The lack of a press release is not surprising if you monitor the landscape of the clinical trials and the lack of success the past 30 years. As an example, the following tweet from a respected AD source,
Phase 2a trial of @Anavex_News presented at #CTAD2016: favourable safety profile, reduction in insomnia and stability on MMSE at week 57 pic.twitter.com/57lNR0T8fm
Jean Georges ?@JeanGeorgesAE Dec 10 Phase 2a trial of @Anavex_News presented at #CTAD2016: favourable safety profile, reduction in insomnia and stability on MMSE at week 57
was met with the following reaction and subsequent response,
Using the word "cure" for phase 2 results would be premature, but also irresponsible! #HOPEnotHYPEJean Georges added,
#HopeNotHype is what Anavex wants to convey, and the company wants to refrain from giving the idea that they have a "cure". Prudent at this point in time.